{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:14:44Z","timestamp":1793499284932,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>Acromegaly is caused by somatotroph tumors. Recently, the WHO recommended the use of transcription factors (TFs) together with pituitary hormones to accurately classify the subtypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to evaluate differences in the clinical and prognostic characteristics of acromegaly patients with different pathological types.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study was conducted on 94 acromegaly patients who underwent surgical treatment. Patients were classified into two groups on the basis of TFs expression by IHC. PIT1 tumors were positive only for PIT1, and PIT1\/SF1 tumors were positive for both PIT1 and SF1. Additionally, on the basis of the expression of GH and PRL by IHC, PIT1 tumors were further subdivided into GH positive tumors (those positive for only GH) and GH\/PRL positive tumors (those positive for both GH and PRL). Differences in clinical and prognostic features among the pathological groups were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PIT1\/SF1 tumors represented 30.9% (n = 29) of the acromegaly patients in this cohort. PIT1\/SF1 tumors had a higher baseline IGF-1 index (2.77 \u00b1 0.73 vs. 2.39 \u00b1 0.74, <jats:italic>P<\/jats:italic> = 0.024) than PIT1 tumors. Despite the higher proportion of postoperative GH &amp;lt; 1 \u03bcg\/L, the biochemical remission rate of PIT1\/SF1 tumors (30.8% vs. 27.6%, <jats:italic>P<\/jats:italic> = 0.812) was similar to that of PIT1 tumors. Compared with those with GH positive tumors, patients with GH\/PRL positive tumors were younger at diagnosis (42.50 \u00b1 13.36 vs. 49.05 \u00b1 11.69, <jats:italic>P<\/jats:italic> = 0.046), and the proportion of male patients was higher (50.0% vs. 23.3%, <jats:italic>P<\/jats:italic> = 0.048). Furthermore, patients with GH\/PRL positive tumors had a significantly higher postoperative GH level [7.30 (3.18\u201311.08) vs. 2.49 (1.57\u20136.84), <jats:italic>P<\/jats:italic> = 0.011] and IGF-1 index (1.82 \u00b1 0.94 vs. 1.31 \u00b1 0.63, <jats:italic>P<\/jats:italic> = 0.011) during follow-up. The biochemical remission rate in GH\/PRL positive tumors was lower, but the difference was not statistically significant (18.2% vs. 37.2%, <jats:italic>P<\/jats:italic> = 0.159).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PIT1\/SF1 tumors represent approximately 30.0% of acromegaly patients. Despite higher baseline IGF-1 levels, the clinical and prognostic features of patients with PIT1\/SF1 tumors are similar to those of patients with PIT1 tumors. GH\/PRL positive tumors, characterized by their earlier age at diagnosis and male predominance, tend to exhibit a lower biochemical remission rate compared to GH positive tumors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1571598","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:13:42Z","timestamp":1747023222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of the clinical and prognostic characteristics of patients with different pathological types in acromegaly"],"prefix":"10.3389","volume":"16","author":[{"given":"Liye","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.867965","article-title":"Acromegaly caused by ectopic growth hormone releasing hormone secretion: A review","volume":"13","author":"Zendran","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0004","article-title":"From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal","volume":"24","author":"Asa","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-023-09777-x","article-title":"Multilineage pituitary neuroendocrine tumors (PitNETs) expressing PIT1 and SF1","volume":"34","author":"Asa","year":"2023","journal-title":"Endocr Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3171\/2022.12.JNS222118","article-title":"Pituitary adenomas with multiple cell lineage combinations: clinicopathological features and short-term prognosis","volume":"139","author":"Tang","year":"2023","journal-title":"J Neurosurg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0328","article-title":"Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1","volume":"12","author":"Fookeerah","year":"2023","journal-title":"Endocr Connect"},{"key":"B10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1530\/eje-11-1119","article-title":"The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases","volume":"166","author":"Wang","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-9136(199807)15:7<539::Aid-dia668>3.0.Co;2-s","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetes Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0288","article-title":"The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp","volume":"95","author":"Guerrero-Romero","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/bf00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02655-0","article-title":"A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal","volume":"475","author":"Villa","year":"2019","journal-title":"Virchows Arch"},{"key":"B16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.3390\/cells11233846","article-title":"Transcriptomic classification of pituitary neuroendocrine tumors causing acromegaly","volume":"11","author":"Rymuza","year":"2022","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000533692","article-title":"DNA methylation pattern in somatotroph pituitary neuroendocrine tumors","volume":"114","author":"Kober","year":"2024","journal-title":"Neuroendocrinology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00401-024-02686-1","article-title":"Pituitary neuroendocrine tumors with PIT1\/SF1 co-expression show distinct clinicopathological and molecular features","volume":"147","author":"Dottermusch","year":"2024","journal-title":"Acta Neuropathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0016-8","article-title":"Epidemiology and biomarker profile of pituitary adenohypophysial tumors","volume":"31","author":"Mete","year":"2018","journal-title":"Modern Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000002846","article-title":"Clinical and pathological features of pit1\/SF1 multilineage pituitary neuroendocrine tumor","volume":"95","author":"Wang","year":"2024","journal-title":"Neurosurgery"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki","year":"2017","journal-title":"Pituitary"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04082-x","article-title":"Co-expression of multiple transcription factors is associated with clinical features and endocrine prognosis in growth hormone-secreting pituitary adenomas","volume":"87","author":"Zhang","year":"2024","journal-title":"Endocrine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.3171\/2010.7.FOCUS10155","article-title":"Patterns of extrasellar extension in growth hormone-secreting and nonfunctional pituitary macroadenomas","volume":"29","author":"Zada","year":"2010","journal-title":"Neurosurg Focus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/10668969231183712","article-title":"Plurihormonal pituitary neuroendocrine tumours - A single centre experience","volume":"32","author":"Mihajlovic","year":"2024","journal-title":"Int J Surg Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0543-OA","article-title":"Clinicopathological correlates of PIT1 and SF1-multilineage pituitary neuroendocrine tumors and the diagnostic utility of NKX2.2 immunohistochemistry in pituitary pathology","volume":"32","author":"Dogukan","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/eje-20-1448","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose","volume":"184","author":"Hage","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01504","article-title":"Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas","volume":"104","author":"Hage","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1060","article-title":"Gipr is essential for adrenocortical steroidogenesis; however, corticosterone deficiency does not mediate the favorable metabolic phenotype of Gipr(-\/-) mice","volume":"61","author":"Bates","year":"2012","journal-title":"Diabetes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.807054","article-title":"Hyperprolactinemia and hypopituitarism in acromegaly and effect of pituitary surgery: long-term follow-up on 529 patients","volume":"12","author":"Guo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3171\/2018.4.Jns18230","article-title":"Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes","volume":"131","author":"Rick","year":"2019","journal-title":"J Neurosurg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01075-7","article-title":"Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly","volume":"23","author":"Varlamov","year":"2020","journal-title":"Pituitary"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02029-1","article-title":"Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up","volume":"66","author":"Lv","year":"2019","journal-title":"Endocrine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae126","article-title":"Differences between GH- and PRL-cosecreting and GH-secreting pituitary adenomas: a series of 604 cases","volume":"109","author":"Araujo-Castro","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae262","article-title":"GH and prolactin co-secreting adenomas: it is time for a definition","volume":"110","author":"Wildemberg","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1055\/a-1207-1132","article-title":"Hyperprolactinemia in acromegaly is related to prolactin secretion by somatolactotroph tumours","volume":"52","author":"Van Laethem","year":"2020","journal-title":"Horm Metab Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01063-x","article-title":"Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review","volume":"23","author":"Agrawal","year":"2020","journal-title":"Pituitary"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-23197","article-title":"A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin","volume":"34","author":"De Marinis","year":"2002","journal-title":"Horm Metab Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1571598\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:13:42Z","timestamp":1747023222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1571598\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":38,"alternative-id":["10.3389\/fendo.2025.1571598"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1571598","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"article-number":"1571598"}}